key: cord-0701934-ug7v07ps authors: Valle, Coralie; Martin, Baptiste; Touret, Franck; Shannon, Ashleigh; Canard, Bruno; Guillemot, Jean‐Claude; Coutard, Bruno; Decroly, Etienne title: Drugs against SARS‐CoV‐2: What do we know about their mode of action? date: 2020-08-11 journal: Rev Med Virol DOI: 10.1002/rmv.2143 sha: fa7e7323837514f0624616b17ceccf6a4b065599 doc_id: 701934 cord_uid: ug7v07ps The health emergency caused by the recent Covid‐19 pandemic highlights the need to identify effective treatments against the virus causing this disease (SARS‐CoV‐2). The first clinical trials have been testing repurposed drugs that show promising anti‐SARS‐CoV‐2 effects in cultured cells. Although more than 2400 clinical trials are already under way, the actual number of tested compounds is still limited to approximately 20, alone or in combination. In addition, knowledge on their mode of action (MoA) is currently insufficient. Their first results reveal some inconsistencies and contradictory results and suggest that cohort size and quality of the control arm are two key issues for obtaining rigorous and conclusive results. Moreover, the observed discrepancies might also result from differences in the clinical inclusion criteria, including the possibility of early treatment that may be essential for therapy efficacy in patients with Covid‐19. Importantly, efforts should also be made to test new compounds with a documented MoA against SARS‐CoV‐2 in clinical trials. Successful treatment will probably be based on multitherapies with antiviral compounds that target different steps of the virus life cycle. Moreover, a multidisciplinary approach that combines artificial intelligence, compound docking, and robust in vitro and in vivo assays will accelerate the development of new antiviral molecules. Finally, large retrospective studies on hospitalized patients are needed to evaluate the different treatments with robust statistical tools and to identify the best treatment for each Covid‐19 stage. This review describes different candidate antiviral strategies for Covid‐19, by focusing on their mechanism of action. This review describes different candidate antiviral strategies for Covid-19, by focusing on their mechanism of action. • Several studies identified compounds that limit SARS-CoV-2 replication in vitro and determined the mode of action of some promising antiviral drugs. • Drug repurposing for Covid-19 treatment is in progress, and the mode of action of these compounds needs to be clarified. Over the last 20 years, three coronaviruses (CoVs) that cause severe pulmonary infections in humans have crossed the species barrier. 1, 2 The last of these CoVs, named SARS-CoV-2, emerged in the Hubei province (China) in December 2019, and rapidly spread worldwide becoming a major public health threat. 3 In approximately 20% of patients, the disease progresses to severe pneumonia, respiratory and multi-visceral failure, often leading to death of patients with comorbidity. 4 This worsening is associated with a deregulated immune response, including exacerbated production of pro-inflammatory cytokines. 5 Therefore, specific and effective antiviral therapies are urgently needed, due to the absence of a vaccine. 6 The virus life cycle, described in Figure 1 , begins by the attachment of the viral particle to the F I G U R E 1 SARS-CoV-2 life cycle and potential mechanisms of action of currently evaluated therapeutics. SARS-CoV-2 life cycle and the presumed mechanisms of action (MoA) of the main SARS-CoV-2 replication inhibitors. Different compounds are assessed to find compounds targeting the different steps of SARS-CoV-2 life cycle. Molecules currently in clinical trials are indicated by a gray star. Therapeutic strategies based on antiviral compounds are indicated in red, and approved drugs used for other diseases or selected by virtual screening are indicated in yellow. The black question marks indicate unknown or elusive MoA in the context of CoV infection. *Corresponding to antibody (Ab) strategies including monoclonal antibodies and plasma from convalescent patient. The Biorender website was used to generate this figure angiotensin-converting enzyme 2 (ACE2) cell surface receptor, mediated by the S protein. 7, 8 Virus entry is achieved by endocytosis and/or direct fusion of the cell and viral membranes. This step requires S protein activation. The S protein is synthesized as an inactive precursor that is inserted in the viral membrane, and requires two subsequent cleavages by cellular proteases to become functionally active. Different cellular proteases, such as furin-like enzymes and the transmembrane protease serine 2 (TMPRSS2), may cleave the S protein in two subunits, S1 and S2, in a process called "priming." 9,10 A recent study showed that this furin-mediated cleavage is important for virus entry in lung cells. 11 In addition, for virus entry, a second proteolytic cleavage is required at the S2 0 site localized immediately upstream of the fusion peptide, 12,13 and seems to involve at least TMPRSS2. 14 The viral genome is then released into the cytoplasm of the infected cells. This allows the translation of the viral mRNA into two polyprotein precursors, pp1a and pp1ab, controlled by a −1 ribosomal frameshift. In the absence of specific therapeutics, supportive care (eg, oxygen therapy or mechanical ventilation) remains the only option for managing severe Covid-19 symptoms. 16 A useful therapeutic strategy consists in interfering with the first step of the viral cycle by targeting the interaction of the viral S protein with the cell surface receptors. It was recently demonstrated that sera from patients with Covid-19 contain neutralizing antibodies (Abs) that can limit SARS-CoV-2 viral infection in vitro. 17 Moreover, administration of plasma from convalescent patients has shown some efficacy in patients with respiratory distress, suggesting that passive immunity might help limit SARS-CoV-2 infection. [18] [19] [20] Clinical trials using plasmapheresis are under way to evaluate the efficacy of this strategy. 21, 22 Nevertheless, recent randomized clinical trial have not shown significant improve for patient under convalescent plasma therapy. 23 The development of monoclonal Abs (mAbs) against the viral S protein is also an option. 24 This approach was used in the latest Ebola outbreak and led to the development of ZMapp. 25 Neutralizing mAbs against the SARSand MERS-CoV S protein have antiviral effect in cultured cells and animals infected with SARS-CoV or MERS-CoV. [26] [27] [28] [29] [30] Thus, the development of mAbs targeting the S protein is currently in progress. 31 The development of mAbs against ACE2 is also an interesting option to reduce viral entry, 32,33 but could be more risky due to potential interference with the physiological function of the ACE2 receptor, which is involved in angiotensin maturation. Another possibility is to use human recombinant soluble ACE2 to block SARS-CoV-2 entry into the cell. 34 This strategy seems to limit SARS-CoV-2 infection in cell culture, but the stability of the soluble receptor in the serum of infected patients and the potential adverse effects in patients remain to be determined. Notably, it has also been shown that ACE2 therapy protects mice from lung injury that can be observed during SARS-CoV infection. 35 Interestingly, mAbs against other cellular receptors, such as CD147, also can block viral infection in cell culture, and the direct interaction between CD147 and the S protein has been demonstrated by coimmunoprecipitation. 36 These first results need be confirmed, but they suggest that SARS-CoV-2 could use an alternative entry receptor in some cell types. A clinical trial using an anti-CD147 antibody (meplazumab) is currently ongoing in China 37 ; however, its antiviral effect is uncertain because the virus binds with higher affinity to the ACE2 receptor. 33 Although SARS-CoV-2 has spread very recently, several antiviral compounds previously tested against other pathogenic CoVs have been already tried patients with Covid-19 ( Table 1 ). The first strategy is to interfere with virus entry using molecules that block virus-cell fusion. This includes umifenovir (Arbidol), an antiviral molecule initially developed for the treatment of influenza infection. 62 Interestingly, umifenovir has a broad spectrum antiviral activity by inhibiting the entry of other viruses 63 and stimulating the immune response. 38 Moreover, umifenovir inhibits SARS-CoV-2 infection in vitro with an IC 50 of 10 μM. 39 Although not yet approved by the FDA, this broadspectrum antiviral molecule is used in China and Russia for influenza treatment, and therefore was rapidly included in several clinical trials alone or in combination with other compounds. The first comparative study performed in a small group of patients showed a significant decrease of the viral load in the arm treated with umifenovir in combination with the protease inhibitors lopinavir/ritonavir (n = 16) compared with the arm treated with lopinavir/ritonavir alone (n = 17). 41 Nevertheless, one of the limitations of this study is the small-sample size and investigation including large cohort need to be performed. remdesivir in a small cohort (n = 53). Notably however, these studies were not randomized and furthermore did not report the change in viral load following treatment. 50 While some adverse effects were reported, including abnormal liver function, diarrhea, rashes, renal impairment, and hypotension, remdesivir was licensed in May 2020 as an emergence treatment against SARS-CoV-2. The cytidine analog β-d-N4-hydroxycytidine (NHC) also is a poten- As some patients with Covid-19 show an inefficient antiviral response, it has been suggested that immunomodulators might restore the immune system homeostasis. Finally, Dexamethasone, used to reduce inflammation, has been tested in RECOVERY clinical trial and shown first promising results. Indeed, treatment with Dexamethasone reduces death by one-third to one-fifth. 91 Several therapeutic molecules (Table 2) , identified in antiviral screenings performed in infected cells, target the renin/angiotensin pathway. 39 ,100,101 The MoA of these class of inhibitors is speculative. Interestingly, ACE2 belongs to this pathway. An in vivo study has shown that inhibition of the renin/angiotensin pathway upregulates of ACE2 which can increase susceptibility to SARS-CoV-2 infection. 102 More recently, it has been shown that treatment target this pathway is not associated with higher severity of COVID19 103 Additional work is needed to understand how these compounds inhibit the virus before planning clinical trials. Once the virus binds to the target cell, the S protein is cleaved by cellular proteases into the S1 and S2 subunits (priming), and also upstream of the fusion peptide (S2' cleavage site). The serine protease TMPRSS2, which is strongly expressed in lung cells, can cleave a variety of CoV S proteins, 12,13 and seems to play a key role in virus entry. 14 Camostat mesylate, a TMPRSS2 inhibitor approved for clinical use, blocks S protein processing in vitro. 92 98 Azithromycin is an antibiotic that has also antiviral activity in respiratory viral infections. 111 Interestingly, the MoA of azithromycin and HCQ may be related to the modulation of the endosomal and trans-Golgi network pH. 112, 113 In addition, azithromycin plays a role in regulating interleukin production that might help to control the immune response and prevent symptom worsening. [114] [115] [116] Azithromycin may also inhibit viral invasion by interfering with the CD147-mediated recognition mechanism. 117 Finally, oseltamivir, a neuraminidase inhibitor that prevents influenza viral particle release, is also investigated. 123 Like for ritonavir/ lopinavir, there is no molecular basis to support these trials because to the best of our knowledge, CoVs (unlike influenza viruses) do not rely on neuraminidases during their life cycle. If antiviral effect are observed, the off-target mechanisms will have to be elucidated. The authors have no competing interest. A novel coronavirus associated with severe acute respiratory syndrome Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia A new coronavirus associated with human respiratory disease in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical features of patients infected with 2019 novel coronavirus in Wuhan SARS and MERS: recent insights into emerging coronaviruses Receptor recognition mechanisms of coronaviruses: a decade of structural studies Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decadelong structural studies of SARS coronavirus The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2 A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites Host cell proteases: critical determinants of coronavirus tropism and pathogenesis TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets A real-time dashboard of clinical trials for COVID-19 Clinical Management of Severe Acute Respiratory Infection When COVID-19 Is Suspected Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 Use of convalescent plasma therapy in SARS patients in Hong Kong The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital Convalescent plasma as a potential therapy for COVID-19 Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and lifethreatening COVID-19 Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: the antigen scale Therapeutic strategies to target the Ebola virus life cycle Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 The discovery of angiotensinconverting enzyme 2 and its role in acute lung injury in mice SARS-CoV-2 invades host cells via a novel route: CD147-spike protein Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial Arbidol: a broadspectrum antiviral compound that blocks viral fusion in vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study Favipiravir versus arbidol for COVID-19: a randomized clinical trial Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro European Clinical Trial Against COVID-19 | Newsroom | INSERM Compassionate use of remdesivir for patients with severe Covid-19 Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering, in press An orally bioavailable broadspectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Small-molecule antiviral β-D-N 4 -hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance Remdesivir is a directacting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR Screening of an FDAapproved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol Broad-spectrum antivirals against viral fusion A large-scale drug repositioning survey for SARS-CoV-2 antivirals The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen Nucleoside analogues for the treatment of coronavirus infections Mechanism of action of interferon and ribavirin in treatment of hepatitis C Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics Severe acute respiratory syndromerelated coronavirus is inhibited by interferon-α Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV In vitro and in vivo activities of anti-influenza virus compound T-705 Favipiravir and ribavirin inhibit replication of Asian and African strains of Zika virus in different cell models The viral polymerase inhibitor 7-deaza-2'-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral T-705) inhibits in vitro norovirus replication Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Treatment of SARS with human interferons Interferon-β 1a and SARS coronavirus replication Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies Coronavirus breakthrough: dexamethasone is first drug shown to save lives Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option. The Currently Unfolding Coronavirus Pandemic Threatens Health Systems and Economies Chloroquine is a potent inhibitor of SARS coronavirus infection and spread In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial The FDAapproved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade Association of angiotensinconverting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Effects of chloroquine on viral infections: an old drug against today's diseases High-density miniaturized thermal shift assays as a general strategy for drug discovery A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology Statement on IJAA Paper. International Society of Antimicrobial Chemotherapy Azithromycin induces anti-viral responses in bronchial epithelial cells Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells Macrolides and viral infections: focus on azithromycin in COVID-19 pathology Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants Azithromycin for the prevention of COPD exacerbations: the good, bad, and ugly Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin Usefulness of Ivermectin in COVID-19 Illness Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens Influenza virus neuraminidase inhibitors Drugs against SARS-CoV-2: What do we know about their mode of action